Skip to content
The Policy VaultThe Policy Vault

Vytorin 10/80 mg — CareFirst (Caremark)

Reduction of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes who are at high risk of coronary heart disease events

Initial criteria

  • Patient has been taking the 10/80 mg strength of ezetimibe/simvastatin (Vytorin) OR the 80 mg strength of simvastatin (Zocor) chronically for 12 months or more

Approval duration

36 months